<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074823</url>
  </required_header>
  <id_info>
    <org_study_id>Ketamine 3 doses</org_study_id>
    <nct_id>NCT05074823</nct_id>
  </id_info>
  <brief_title>Comparing Three Different Doses of Intrathecal Ketamine</brief_title>
  <official_title>Analgesic Effects of Three Different Doses of Intrathecal Ketamine as an Adjuvant to Intrathecal Bupivacaine in Patients Undergoing Knee Arthroscopy. A Randomized Prospective Double-blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the postoperative analgesic effect of three different&#xD;
      doses of intrathecal ketamine as an adjuvant to bupivacaine in patients undergoing knee&#xD;
      arthroscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A meta-analysis of adult human randomized controlled studies that compared single dose&#xD;
      perioperative intrathecal ketamine plus intrathecal bupivacaine to bupivacaine alone in&#xD;
      spinal anesthesia suggests that there is a benefit to using intrathecal ketamine as an&#xD;
      adjunct to bupivacaine in multimodal analgesia. However, there are still knowledge and&#xD;
      experience gaps regarding neuraxial ketamine dosing in this regard.&#xD;
&#xD;
      Aim of the study:&#xD;
&#xD;
      The aim of this study is to compare the postoperative analgesic effect of three different&#xD;
      doses of intrathecal ketamine as an adjuvant to bupivacaine in patients undergoing knee&#xD;
      arthroscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2022</start_date>
  <completion_date type="Anticipated">August 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first analgesic request</measure>
    <time_frame>First 24 hours</time_frame>
    <description>From the time of intrathecal administration of the drug to the time of patient needs the first rescue analgesic drug</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Ketamine Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>Ketamine 0.1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group I: will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group II will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group III will include 35 patients, will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.1 mg</intervention_name>
    <description>Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg</description>
    <arm_group_label>Ketamine 0.1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.2 mg</intervention_name>
    <description>will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg</description>
    <arm_group_label>Ketamine 0.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.3 mg</intervention_name>
    <description>will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg</description>
    <arm_group_label>Ketamine 0.3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-70 years.&#xD;
&#xD;
          -  BMI: 20-30 kg.m2&#xD;
&#xD;
          -  Sex: both males and females.&#xD;
&#xD;
          -  ASA physical status: I-III.&#xD;
&#xD;
          -  Operation: knee arthroscopy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's refusal to participate in the study.&#xD;
&#xD;
          -  Aged less than 18 years,&#xD;
&#xD;
          -  known allergy to L.A.,&#xD;
&#xD;
          -  Coagulopathy or thrombocytopenia,&#xD;
&#xD;
          -  height less than 150 cm, morbidly obese infection at the site of injection.&#xD;
&#xD;
          -  Chronic pain syndromes,&#xD;
&#xD;
          -  pregnant woman&#xD;
&#xD;
          -  Patients on regular use of analgesic or who received analgesic 24 h before surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mostafa S Abbas, MD</last_name>
    <phone>01003060187</phone>
    <email>mostafasamy@aun.edu.eg</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mostafa Samy Abbas</investigator_full_name>
    <investigator_title>associate professor of anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

